Cytokinetics (CYTK) Stock Statistics & Valuation Metrics

Cytokinetics has a market cap or net worth of $10.61B. The enterprise value is $10.88B.

Cytokinetics has 124,432,560 shares outstanding. The number of shares has decreased by -2.65% in one year.

Cytokinetics’s return on equity (ROE) is 1.19 and return on invested capital (ROIC) is -47.74%.

The current PE Ratio of Cytokinetics is ―. Cytokinetics’s PEG ratio is -0.40.

In the last 12 months, Cytokinetics had revenue of 88.04M and earned -784.96M in profits. Earnings per share was -6.54.

In the last 12 months, operating cash flow was -523.85M and capital expenditures -25.07M, giving a free cash flow of -548.92M billion.

Cytokinetics pays an annual dividend of ―, resulting in a dividend yield of ―

Cytokinetics upcoming earnings date is Jul 30, 2026, After Close (Confirmed).

Cytokinetics as a current ratio of 4.53, with Debt / Equity ratio of -155.91%

In the past 12 months, Cytokinetics has paid 0.00 in taxes.

Cytokinetics EV to EBITDA ratio is -11.34, with an EV/FCF ratio of -16.43.

Cytokinetics has $818.55M in cash and marketable securities with $1.29B in debt, giving a net cash position of -$470.17M billion.

Gross margin is 90.34%, with operating margin of -695.44%, and net profit margin of -891.60%.

The average price target for Cytokinetics is $106.53, which is 11.43% higher than the current price. The consensus rating is Strong Buy